Free Trial

Jonathan Miller Analyst Performance

Analyst at Evercore

Jonathan Miller is a stock analyst at Evercore in the medical sector, covering 3 publicly traded companies. Over the past year, Jonathan Miller has issued 2 stock ratings, including buy and hold recommendations. While full access to Jonathan Miller's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jonathan Miller's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 4 Years
Buy Recommendations
33.33% 1 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy33.3%1 ratings
Hold66.7%2 ratings
Sell0.0%0 ratings

Out of 3 total stock ratings issued by Jonathan Miller at Evercore, the majority (66.7%) have been Hold recommendations, followed by 33.3% Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
3 companies

Jonathan Miller, an analyst at Evercore, currently covers 3 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
3 companies
100.0%

Jonathan Miller of Evercore specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
2 companies
66.7%
PHARMACEUTICAL PREPARATIONS
1 company
33.3%

Jonathan Miller's Ratings History at Evercore

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
11/25/2025Initiated Coverage$6.11Outperform
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
11/11/2025Set Price Target$9.73$8.00In-Line